1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lymphoma.
2. Assess the prognostic impact of cancer-related molecular biology testing for a patient with lymphoma.
3. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.